AAAAAA
Results:
1-25
|
Results: 25
Authors:
Brosen, K
Naranjo, CA
Citation: K. Brosen et Ca. Naranjo, Review of pharmacokinetic and pharmacodynamic interaction studies with citalopram, EUR NEUROPS, 11(4), 2001, pp. 275-283
Authors:
Bergmann, TK
Bathum, L
Brosen, K
Citation: Tk. Bergmann et al., Duplication of CYP2D6 predicts high clearance of desipramine but high clearance does not predict duplication of CYP2D6, EUR J CL PH, 57(2), 2001, pp. 123-127
Authors:
Madsen, H
Enggaard, TP
Hansen, LL
Klitgaard, NA
Brosen, K
Citation: H. Madsen et al., Fluvoxamine inhibits the CYP2C9 catalyzed biotransformation of tolbutamide, CLIN PHARM, 69(1), 2001, pp. 41-47
Authors:
Kirchheiner, J
Brosen, K
Dahl, ML
Gram, LF
Kasper, S
Roots, I
Sjoqvist, F
Spina, E
Brockmoller, J
Citation: J. Kirchheiner et al., CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages, ACT PSYC SC, 104(3), 2001, pp. 173-192
Authors:
Rasmussen, BB
Brosen, K
Citation: Bb. Rasmussen et K. Brosen, Is therapeutic drug monitoring a case for optimizing clinical outcome and avoiding interactions of the selective serotonin reuptake inhibitors?, THER DRUG M, 22(2), 2000, pp. 143-154
Authors:
Damkier, P
Brosen, K
Citation: P. Damkier et K. Brosen, Quinidine as a probe for CYP3A4 activity: Intrasubject variability and lack of correlation with probe-based assays for CYP1A2, CYP2C9, CYP2C19, and CYP2D6, CLIN PHARM, 68(2), 2000, pp. 199-209
Authors:
Fjordside, L
Jeppesen, U
Eap, CB
Powell, K
Baumann, P
Brosen, K
Citation: L. Fjordside et al., The stereoselective metabolism of fluoxetine in poor and extensive metabolizers of sparteine, PHARMACOGEN, 9(1), 1999, pp. 55-60
Authors:
Buur-Rasmussen, B
Brosen, K
Citation: B. Buur-rasmussen et K. Brosen, Cytochrome P450 and therapeutic drug monitoring with respect to clozapine, EUR NEUROPS, 9(6), 1999, pp. 453-459
Authors:
Damkier, P
Hansen, LL
Brosen, K
Citation: P. Damkier et al., Rifampicin treatment greatly increases the apparent oral clearance of quinidine, PHARM TOX, 85(6), 1999, pp. 257-262
Authors:
Damkier, P
Hansen, LL
Brosen, K
Citation: P. Damkier et al., Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine, BR J CL PH, 48(6), 1999, pp. 829-838
Authors:
Larsen, JT
Hansen, LL
Brosen, K
Citation: Jt. Larsen et al., Tacrine is not an ideal probe drug for measuring CYP1A2 activity in vivo, BR J CL PH, 48(5), 1999, pp. 663-668
Authors:
Bathum, L
Skjelbo, E
Mutabingwa, TK
Madsen, H
Horder, M
Brosen, K
Citation: L. Bathum et al., Phenotypes and genotypes for CYP2D6 and CYP2C19 in a black Tanzanian population, BR J CL PH, 48(3), 1999, pp. 395-401
Tramadol relieves pain and allodynia in polyneuropathy: a randomised, double-blind, controlled trial
Authors:
Sindrup, SH
Andersen, G
Madsen, C
Smith, T
Brosen, K
Jensen, TS
Citation: Sh. Sindrup et al., Tramadol relieves pain and allodynia in polyneuropathy: a randomised, double-blind, controlled trial, PAIN, 83(1), 1999, pp. 85-90
Authors:
Hansen, LL
Brosen, K
Citation: Ll. Hansen et K. Brosen, Quantitative determination of tolbutamide and its metabolites in human plasma and urine by high-performance liquid chromatography and UV detection, THER DRUG M, 21(6), 1999, pp. 664-671
Authors:
Damkier, P
Hansen, LL
Brosen, K
Citation: P. Damkier et al., Effect of fluvoxamine on the pharmacokinetics of quinidine, EUR J CL PH, 55(6), 1999, pp. 451-456
Authors:
Larsen, JT
Hansen, LL
Spigset, O
Brosen, K
Citation: Jt. Larsen et al., Fluvoxamine is a potent inhibitor of tacrine metabolism in vivo, EUR J CL PH, 55(5), 1999, pp. 375-382
Authors:
Kortunay, S
Bozkurt, A
Bathum, L
Basci, NE
Calguneri, M
Brosen, K
Kayaalp, SO
Citation: S. Kortunay et al., CYP2D6 polymorphism in systemic lupus erythematosus patients, EUR J CL PH, 55(1), 1999, pp. 21-25
Authors:
Ibeanu, GC
Blaisdell, J
Ferguson, RJ
Ghanayem, BI
Brosen, K
Benhamou, S
Bouchardy, C
Wilkinson, GR
Dayer, P
Goldstein, JA
Citation: Gc. Ibeanu et al., A novel transversion in the intron 5 donor splice junction of CYP2C19 and a sequence polymorphism in exon 3 contribute to the poor metabolizer phenotype for the anticonvulsant drug S-mephenytoin, J PHARM EXP, 290(2), 1999, pp. 635-640
Authors:
Nielsen, TL
Rasmussen, BB
Flinois, JP
Beaune, P
Brosen, K
Citation: Tl. Nielsen et al., In vitro metabolism of quinidine: The (3S)-3-hydroxylation of quinidine isa specific marker reaction for cytochrome P-4503A4 activity in human livermicrosomes, J PHARM EXP, 289(1), 1999, pp. 31-37
Authors:
Sindrup, SH
Madsen, C
Brosen, K
Jensen, TS
Citation: Sh. Sindrup et al., The effect of tramadol in painful polyneuropathy in relation to serum drugand metabolite levels, CLIN PHARM, 66(6), 1999, pp. 636-641
Clomipramine dose-effect study in patients with depression: Clinical end points and pharmacokinetics
Authors:
Glue, P
Andersen, KO
Hansen, MA
Stage, KB
Hansen, H
Norrie, B
Hansen, PEB
Knudsen, L
Thomsen, R
Pedersen, I
Jessen, IM
Haffner, F
Hansen, JB
Berthou, E
Kierkegaard, H
Andersen, TH
Bjarking, L
Bech, P
Bendsen, BB
Spanager, S
LaBianca, J
Jha, S
Hoybye, E
Bysted, M
Rasmussen, NA
Moller, AG
Welter, H
Justesen, EM
Merinder, L
Andersen, F
Bartels, U
Borg, L
Christensen, J
Weeke, A
Raben, H
Larsen, JK
Knudsen, H
Jorgensen, O
Knudsen, AF
Horsboll, H
Waago, K
Christensen, B
Christensen, NB
Thiesen, S
Wernlund, HH
Thomsen, IS
Christensen, EM
Skovgaard, K
Andersen, J
Andersen, M
Gram, LF
Brosen, K
Sindrup, SH
Fugmann, S
de Lasson, AR
Andersen, D
Gram, LF
Kragh-Sorensen, P
Bech, P
Bolwig, TG
Vestergaard, P
Larsen, JK
Citation: P. Glue et al., Clomipramine dose-effect study in patients with depression: Clinical end points and pharmacokinetics, CLIN PHARM, 66(2), 1999, pp. 152-165
Authors:
Kortunay, S
Bozkurt, A
Bathum, L
Basci, NE
Calguneri, M
Brosen, K
Kayaalp, SO
Citation: S. Kortunay et al., CYP2C19 genotype does not represent a genetic predisposition in idiopathicsystemic lupus erythematosus, ANN RHEUM D, 58(3), 1999, pp. 182-185
Authors:
Christensen, PM
Gotzsche, PC
Brosen, K
Citation: Pm. Christensen et al., The sparteine/debrisoquine (CYP2D6) oxidation polymorphism and the risk ofParkinson's disease: a meta-analysis, PHARMACOGEN, 8(6), 1998, pp. 473-479
Authors:
Rasmussen, BB
Nielsen, TL
Brosen, K
Citation: Bb. Rasmussen et al., Fluvoxamine is a potent inhibitor of the metabolism of caffeine in vitro, PHARM TOX, 83(6), 1998, pp. 240-245
Authors:
Rasmussen, BB
Nielsen, TL
Brosen, K
Citation: Bb. Rasmussen et al., Fluvoxamine inhibits the CYP2C19-catalysed metabolism of proguanil in vitro, EUR J CL PH, 54(9-10), 1998, pp. 735-740
Risultati:
1-25
|